Research Article| Volume 26, ISSUE 6, P623-630, October 1989

Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y

      This paper is only available as a PDF. To read, Please Download here.


      The ability to measure directly central nervous system (CNS) neurotransmitter changes after an acute pharmacological challenge would be a useful clinical tool in psychiatric research. As one approach to this possibility, we attempted to measure cerebrospinal fluid (CSF) neuropeptide changes produced by an intravenous infusion of the indirect cholinergic agonist physostigmine. Six rhesus monkeys, with indwelling CSF catheters, had serial CSF samples removed before and after a 15 μg/kg physostigmine infusion. Five of six monkeys studied showed at least a 50% increase in CSF neuropeptide-Y (NPY) levels. Normal human subjects (n = 27) had CSF sampled before and 15, 30, and 45 min after an acute intravenous infusion of physostigmine (either 0, 5, or 15 μg/kg). An Analysis of Variance revealed a significant (p = 0.04) dose-time interaction, suggesting that physostigmine increased CSF NPY at the 15 μg/kg dose. CSF levels of seven other neuropeptides remained unchanged. These results suggest that the pharmacological challenge paradigm can be adapted to CSF neuropeptides, providing new measures of CNS stimulus-induced response beyond the peripheral plasma determinations usually employed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Alien JM
        • Gibson SJ
        • Adrian TE
        • Polak JM
        • Bloom SR
        Neuropeptide Y in spinal cord.
        Brain Res. 1984; 308: 145
        • Berrettini WH
        • Nurnberger Jr, JI
        • Chan JSD
        • Chrousos GP
        • Gaspar L
        • Gold PW
        • Seidah NG
        • Simmons-Alling S
        • Goldin LR
        • Chretien M
        • Gershon ES
        Pro-opiomelanocortin-related peptides in CSF: A study of manic-depressive disorder.
        Psychiatry Res. 1985; 16: 287
        • Berrettini WH
        • Nurnberger Jr, JI
        • Dimaggio DA
        Neuropeptide Y immunoreactivity in human CSF.
        Peptides. 1986; 7: 455
        • Berrettini WH
        • Doran AR
        • Kelsoe J
        • Roy A
        • Pickar D
        Cerebrospinal fluid neuropeptide Y in depression and schizophrenia.
        Neuropsychopharmacology. 1987; 1: 81
        • Berrettini WH
        • Nurnberger Jr, JI
        • Gold PW
        • Zerbe RL
        • Chrousos GP
        • Tomai T
        CSF neuropeptides in euthymic bipolar patients and controls.
        Br J Psychiatry. 1987; 150: 208
        • Berrettini WH
        • Nurnberger Jr, JI
        • Simmons-Alling S
        Growth hormone releasing factor in human CSF.
        Psychiatry Res. 1987; 20: 141
        • Berrettini WH
        • Kaye WH
        • Sunderland T
        • May C
        • Gwirtsman HE
        • Mellow A
        • Albright A
        Galanin immunoreactivity in human CSF: Studies in eating disorders and Alzheimer's disease.
        Neuropsychobiology. 1988; 19: 64
        • Berrettini WH
        • Oxienstierna G
        • Sedvall G
        • Nürnberger Jr, JI
        • Gold PW
        • Rubinow DR
        • Goldin LR
        Characteristics of cerebrospinal fluid neuropeptides relevant to clinical research.
        Psychiatry Res. 1988; 25: 349
        • Davis KL
        • Hollister LE
        • Goodwin FK
        • Gordon EK
        Neurotransmitter metabolites in the cerebrospinal fluid of man following physostigmine.
        Life Sci. 1977; 21: 933
        • Dawburn D
        • Hunt SP
        • Emson PC
        Neuropeptide Y: Regional distribution, Chromatographie characterization and immunohistochemical demonstration in post-mortem human brain.
        Brain Res. 1984; 296: 168
        • Ebeid AM
        • Attia RR
        • Sundaram P
        • Fischer JE
        Release of vasoactive intestinal peptide in the central nervous system.
        Am J Surgery. 1979; 137: 123
        • Garrick NA
        • Hill JL
        • Szele FG
        • Tomai TP
        • Gold PW
        • Murphy DL
        Corticotropin releasing factor: A marked circadian rhythm in primate cerebrospinal fluid peaks in the evening and is inversely related to the corticol circadian rhythm.
        Endocrinology. 1987; 121: 1329
        • Hexum TD
        • Majane EA
        • Russett LR
        • Yang H-YT
        Neuropeptide Y release from the adrenal medulla after cholinergic receptor stimulation.
        J Pharmacol Exp Ther. 1987; 243: 927
        • Janowsky DS
        • El-Yousef MK
        • Davis JM
        Cholinergic-adrenergic hypothesis of mania and depression.
        Lancet. 1972; ii: 632
        • Mesulam MM
        • Mufson EJ
        • Wainer BH
        • Levey AI
        Central cholinergic pathways in the rat: An overview based on alternative nomenclature.
        Neuroscience. 1983; 10: 1185
        • Patel YC
        • Reichlin S
        in: Jaffe BM Behman HR Methods of Hormone Radioimmunoassay. ed 2. Academic Press, Philadelphia1979: 77
        • Perry EK
        • Tomlinson BE
        • Blessed G
        • Bergman K
        • Gibson PH
        • Perry RH
        Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.
        Br Med J. 1978:; 2: 1457
        • Sitaram N
        • Nurnberger Jr, JI
        • Gershon ES
        • Gillin JC
        Faster REM induction in patients with primary affective disorder.
        Science. 1980; 208: 200
        • Tausch A
        • Stegner H
        • Leake RD
        • Artman HG
        • Fisher DA
        Radioimmunoassay of arginine vasopressin in urine.
        J Clin Endocrinol Metab. 1983; 57: 777
        • Whitehouse PJ
        • Price DL
        • Clark AW
        • Coyle JT
        • Delong MA
        Alzheimer's disease and senile dementia—Loss of neurons in the basal forebrain.
        Science. 1982; 215: 1237